Description Lucentis® (ranibizumab injection) is an antibody fragment designed to bind to and inhibit vascular endothelial growth factor (VEGF), a protein that is believed to play a critical role in angiogenesis (the formation of new blood vessels).

Development Status Phase III clinical trials evaluating Lucentis for diabetic macular edema (DME) and retinal vein occlusion (RVO) are ongoing.

Lucentis is being developed in collaboration with Novartis.

Approved Uses

• In June 2006, the U.S. Food and Drug Administration (FDA) approved Lucentis for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Read more about Lucentis' approved use.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

November 2007